NEW YORK, Aug. 3 – Biotech holding company Techne has acquired a 39 percent interest in Discovery Genomics and rights to develop antibodies and immunoassays for proteins targets that Discovery Genomics discovers, Techne said on Friday.

The agreement allows Techne exclusively to sell products based on Discovery Genomics’ discoveries in the research market royalty-free. Techne may also opt to sell similar products in the diagnostic market with obligations to pay royalties to Discovery Genomics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.